Equities

Arcellx Inc

ACLX:NSQ

Arcellx Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)85.43
  • Today's Change4.88 / 6.06%
  • Shares traded752.68k
  • 1 Year change+136.06%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy6
Outperform12
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 15 analysts offering 12 month price targets for Arcellx Inc have a median target of 81.00, with a high estimate of 91.00 and a low estimate of 73.00. The median estimate represents a 0.56% increase from the last price of 80.55.
High13.0%91.00
Med0.6%81.00
Low-9.4%73.00

Earnings history & estimates in USD

On Aug 08, 2024, Arcellx Inc reported 2nd quarter 2024 losses of -0.51 per share. This result was in line with the consensus of the 14 analysts following the company and under-performed last year's 2nd quarter results by 2.00%.
The next earnings announcement is expected on Nov 14, 2024.
Average growth rate-163.14%
Arcellx Inc reported annual 2023 losses of -1.47 per share on Feb 28, 2024.
Average growth rate+84.06%
More ▼

Revenue history & estimates in USD

Arcellx Inc had 2nd quarter 2024 revenues of 27.38m. This bettered the 21.76m consensus of the 11 analysts covering the company. This was 52.88% above the prior year's 2nd quarter results.
Average growth rate+64.67%
Arcellx Inc had revenues for the full year 2023 of 110.32m.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.